Price
CHART BY
Frequently asked questions
What is Arrowhead Pharms's market capitalization?
The market capitalization of Arrowhead Pharms is $9.43B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Arrowhead Pharms?
Arrowhead Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.243. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Arrowhead Pharms's stock?
Currently, 15 analysts cover Arrowhead Pharms's stock, with a consensus target price of $110.91. Analyst ratings provide insights into the stock's expected performance.
What is Arrowhead Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Arrowhead Pharms reported a revenue of $669.50M.
What is the EBITDA for Arrowhead Pharms?
Arrowhead Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$200.64M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Arrowhead Pharms?
Arrowhead Pharms has a free cash flow of -$75.11M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Arrowhead Pharms have, and what sector and industry does it belong to?
Arrowhead Pharms employs approximately 711 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Arrowhead Pharms's shares?
The free float of Arrowhead Pharms is 132.97M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $9.43B
- EPS (TTM)
- -$2.243
- Free Float
- 132.97M
- Revenue (TTM)
- $669.50M
- EBITDA (TTM)
- -$200.64M
- Free Cashflow (TTM)
- -$75.11M
Pricing
- 1D span
- $66.49$67.70
- 52W span
- $30.76$95.43
Analyst Ratings
The price target is $110.91 and the stock is covered by 15 analysts.
Buy
15
Hold
0
Sell
0
Information
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
- Employees
- 711
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- ARWR
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet